RTI International, Research Triangle Park, NC.
Friends Research Institute.
Med Care. 2022 Aug 1;60(8):631-635. doi: 10.1097/MLR.0000000000001743. Epub 2022 Jun 10.
A randomized clinical trial found that patient navigation for hospital patients with comorbid substance use disorders (SUDs) reduced emergency department (ED) and inpatient hospital utilization compared with treatment-as-usual.
To compare the cost and calculate any cost savings from the Navigation Services to Avoid Rehospitalization (NavSTAR) intervention over treatment-as-usual.
This study calculates activity-based costs from the health care providers and uses a net benefits approach to calculate the cost savings generated from NavSTAR. NavSTAR provided patient navigation focused on engagement in SUD treatment, starting before hospital discharge and continuing for up to 3 months postdischarge.
Adult hospitalized medical/surgical patients with comorbid SUD for opioids, cocaine, and/or alcohol.
Cost of the 3-month NavSTAR patient navigation intervention and the cost of all inpatient days and ED visits over a 12-month period.
NavSTAR generated $17,780 per participant in cost savings. Ninety-seven percent of bootstrapped samples generated positive cost savings, and our sensitivity analyses did not change our results.
Participants were recruited at one hospital in Baltimore, MD through the hospital's addiction consultation service. Findings may not generalize to the broader population. Outpatient health care cost data was not available through administrative records.
Our findings show that patient navigation interventions should be considered by payors and policy makers to reduce the high hospital costs associated with comorbid SUD patients.
一项随机临床试验发现,针对患有合并物质使用障碍(SUD)的住院患者的患者导航,与常规治疗相比,可减少急诊部(ED)和住院的就诊次数。
比较导航服务以避免再入院(NavSTAR)干预与常规治疗相比的成本,并计算节省的任何成本。
本研究根据医疗服务提供者计算基于活动的成本,并使用净效益方法计算 NavSTAR 产生的节省成本。NavSTAR 为患有阿片类药物、可卡因和/或酒精合并 SUD 的成年住院医疗/外科患者提供专注于 SUD 治疗参与的患者导航,从出院前开始,并持续 3 个月。
患有合并 SUD 的阿片类药物、可卡因和/或酒精的成年住院医疗/外科患者。
为期 3 个月的 NavSTAR 患者导航干预的成本,以及在 12 个月内所有住院天数和 ED 就诊的成本。
NavSTAR 为每位参与者节省了 17780 美元的成本。97%的自举样本产生了正的成本节省,我们的敏感性分析没有改变结果。
参与者是通过马里兰州巴尔的摩的一家医院的成瘾咨询服务在一家医院招募的。研究结果可能无法推广到更广泛的人群。通过行政记录无法获得门诊医疗成本数据。
我们的研究结果表明,患者导航干预措施应得到支付者和政策制定者的考虑,以降低与合并 SUD 患者相关的高额医院成本。